SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

India’s pharmaceutical supply chain continues to rely heavily on Chinese imports: NITI Aayog

24 Jun 2026 Evaluate

A government think tank NITI Aayog in the eighth edition of its Trade Watch Quarterly report has said that India’s pharmaceutical supply chain continues to rely heavily on China, with around 65 per cent of critical Active Pharmaceutical Ingredients (APIs) and key starting materials being imported from China. It noted that that stricter environmental compliance norms have led to a significant increase in manufacturing and research costs for domestic pharmaceutical companies.

The report also pointed out that a weak innovation and commercialisation ecosystem have created uncertainty for innovators and long-term investments. To strengthen the sector’s global competitiveness, it recommended greater diversification into high-value pharmaceutical segments. It further emphasized the need for improved regulatory transparency and stronger industry-academia collaboration within life-sciences clusters to accelerate patent commercialisation, foster research collaboration, and support startup incubation. 

The report further stated that India remains a leading supplier of affordable generic medicines worldwide, catering to nearly 50 per cent of Africa’s, 40 per cent of the United States’, and 25 per cent of the United Kingdom’s generic drug requirements. Globally, demand for pharmaceuticals reached $1.02 trillion in 2025, while the API market stood at $261 billion, taking the total drugs and pharmaceuticals market to nearly $1.3 trillion. Meanwhile, the report reveals that India’s overall trade expanded by 5.4% year-on-year to $1.84 trillion in the fourth quarter of FY26, underlining the resilience of the Indian economy despite a challenging global trade environment. 


About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: